Wells downgrades Vertex to Equal Weight on lack of catalysts
Wells Fargo analyst Mohit Bansal downgraded Vertex Pharmaceuticals (VRTX) to Equal Weight from Overweight with an unchanged price target of ...
Vertex downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo analyst Mohit Bansal downgraded Vertex Pharmaceuticals (VRTX) to Equal Weight from Overweight with an unchanged price target of ...
Hosted on MSN3d
Earnings Preview: Vertex Pharmaceuticals (VRTX) Q4 Earnings Expected to Decline
Vertex Pharmaceuticals (VRTX) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...